Torrent Pharmaceuticals Announces Q4 FY26 Results, Targets Significant Growth via QIP

Torrent Pharmaceuticals Announces Q4 FY26 Results, Targets Significant Growth via QIP​

Torrent Pharmaceuticals Limited today announced its financial results for the fourth quarter and the full fiscal year of 2026. The company reported robust growth, driven by strong branded performance across key markets, noting that the consolidated financial results incorporate the financial outcomes and acquisition effects of JB Pharma and its subsidiaries, effective January 21, 2026.

The Board of Directors approved the audited financial results for the quarter and year ended March 31, 2026.

Financial Highlights for Q4 FY26 and FY26​

The company reported significant year-over-year increases in revenue and profit. Key highlights for the quarter of April to March 2026 include:

• Revenue reached Rs 4,197 crores, marking a 42% year-over-year (YoY) increase.
• Operating EBITDA was recorded at Rs 1,356 crores, up 41% YoY.
• The Net Profit After Tax (PAT) for the quarter stood at Rs 364 crores.

For the full fiscal year 2026, Torrent Pharmaceuticals reported:

• Total Revenues reached Rs 13,980 crores, a 21% increase YoY.
• Operating EBITDA grew to Rs 4,559 crores, up 23% YoY.
• PAT for FY26 was Rs 2,138 crores, representing a 12% increase YoY.

A comparison of key financials between Q4 FY26 and Q4 FY25 is provided below:

Dividend and Funding Recommendations​

In a corporate action, the Board recommended a final dividend of Rs 9/- per equity share, based on the face value of Rs 5 per share. The proposed payment date is slated for around June 25, 2026.

Furthermore, the company recommended to its members obtaining enabling approval for issuing Equity Shares, including Convertible Bonds/Debentures, through a Qualified Institutional Placement (QIP). This raise is intended for an amount not exceeding ₹ 5,000 crores.

Operational Performance by Geography​

The company's base business performance showed strong regional growth across major markets:


The India business saw revenues of Rs 2,215 crores in Q4 FY26, marking a 43% increase, contributing to FY26 revenues of Rs 7,645 crores, up 20%. In Brazil, revenues reached Rs 455 crores in Q4 FY26, showing a 30% increase, with total FY26 revenue standing at Rs 1,362 crores. Similarly, the US and Germany markets posted strong growth, with the US showing a 31% revenue increase in Q4 FY26.

Acquisition Impact​

The consolidated financial results reflect the Parent Company’s successful acquisition of a controlling stake in JB Pharma, effective January 21, 2026. The parent company acquired the controlling stake through multiple transactions, including an open offer and subsequent share purchases, culminating in the assumption of control.

The financial statements include the results and associated acquisition effects of JB Pharma, its subsidiaries, and the parent company. The consolidation ensures the financial reports reflect the consolidated operational scope and assets of the group.

TORNTPHARM Stock Price Movement​

Today, Torrent Pharmaceuticals Limited shares edged higher to settle at ₹4486.2, gaining 0.62% in post-market trading. The stock maintained momentum, hitting an impressive 52-week high of ₹4555.1, with 205,928 shares traded today.